论文部分内容阅读
《国家医保目录》如期推出,新医保目录有较大幅度扩容,化学药和中药品种相对于2004年版本均有一定的增减,有新增品种进目录的上市公司将明显受益。
The “National Medicare Catalog” was launched on schedule and the catalog of new Medicare has been greatly expanded. There is a certain increase or decrease in chemical medicine and traditional Chinese medicine varieties relative to the 2004 version. Listed companies with new varieties into the catalog will obviously benefit.